So far, the therapies scheduled to be part of the trial are risankizumab, an interleukin-23 antagonist, and lenzilumab, an anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody.
The US Department of Health and Human Services and the Department of Defense have agreed to receive 100 million doses of BNT162, a vaccine for SARS-CoV-2, once the manufacturers obtains approval or emergency use authorization from the FDA.
The analysis included results from 2 tests that have received EUA: the SARS-CoV-2 ELISA test (Euroimmun) and the COVID-19 IgG/IgM Rapid Test Cassette (Healgen).
The first patients have been dosed in a phase 1 trial evaluating a potential antibody therapy designed to treat coronavirus disease 2019. These patients received treatment at major medical centers in the US, including NYU Grossman School of Medicine and Cedars-Sinai in Los Angeles.
The FDA has cleared the Propeller Health digital platform to connect with the Symbicort® Inhaler, a corticosteroid and long-acting beta-2 agonist indicated for the treatment of asthma and COPD.
LabCorp has expanded access to its at-home collection test kit to individuals nationwide who have symptoms consistent with coronavirus disease 2019 and those without symptoms who may have been exposed to the virus.
The impact of COVID-19 on the global health system and economy will likely result in large-scale changes in zoonotic disease prevention preparedness.
Haymarket Medical Network, a part of business media company Haymarket Media, Inc., is proud to join the Ad Council’s first ever Private Marketplace (PMP) along with other partners Cadreon, The Trade Desk and Acxiom.
The American Board of Internal Medicine announced that certified physicians who have a Maintenance of Certification requirement due in 2020 will now have until the end of 2021 to complete it.
A phase 3 study evaluating Ultomiris (ravulizumab-cwvz; Alexion) in hospitalized patients with COVID-19 is expected to begin in May.
